Table 1.
Summary of Demographics and Clinical Characteristics
| All Groups N=358 | Treated and Suppressed N=250 | Untreated and Unsuppressed N=61 | |
|---|---|---|---|
| Demographics | |||
| Age, ya | 50 (43, 56) | 51 (44, 58) | 44 (39, 54) |
| White | 61% | 65% | 52% |
| Black | 22% | 18% | 31% |
| Hispanic | 11% | 12% | 10% |
| Other | 6% | 5% | 7% |
| Male | 84% | 88% | 77% |
| Cardiovascular risk factors | |||
| Hypertension | 42% | 40% | 41% |
| Diabetes mellitus | 8% | 8% | 7% |
| Current smoking | 31% | 25% | 46% |
| Smoking pack yearsa | 2 (0, 15) | 1 (0, 15) | 2 (0, 13) |
| LDL, mg/dLa | 102 (83, 123) | 103 (86, 123) | 102 (80, 127) |
| HDL, mg/dLa | 45 (37, 53) | 45 (37, 55) | 44 (36, 50) |
| Total cholesterol, mg/dLa | 177 (154, 201) | 179 (156, 204) | 171 (148, 198) |
| Triglycerides, mg/dLa | 116 (84, 192) | 122 (89, 202) | 100 (69, 127) |
| HIV‐related factors | |||
| Current CD4, cells/mm3 a | 542 (339, 720) | 535 (319, 709) | 536 (370, 701) |
| Nadir CD4, cells/mm3 a | 188 (45, 315) | 130 (29, 234) | 350 (272, 458) |
| CD4/CD8 ratioa | 0.58 (0.38, 0.92) | 0.62 (0.40, 0.98) | 0.50 (0.32, 0.76) |
| CD8, cells/mm3 a | 892 (666, 1224) | 852 (632, 1105) | 1069 (752, 1393) |
| HIV duration, ya | 15 (7, 20) | 16 (8, 21) | 9 (4, 20) |
| NNRTI use | 51% | 62% | 10% |
| NRTI use | 80% | 100% | 16% |
| Protease inhibitor use | 62% | 78% | 8% |
| Hepatitis C infection | 18% | 15% | 16% |
| Hepatitis B infection | 5% | 4% | 5% |
| Opportunistic infection | 13% | 12% | 8% |
| Neoplasms (non‐skin cancer) | 4% | 5% | 2% |
| Disease categories | |||
| Off ART, VL <75 copies/mL | 7% | — | — |
| Off ART, VL >75 copies/mL | 17% | — | 100% |
| On ART, VL <75 copies/mL | 70% | 100% | — |
| On ART, VL >75 copies/mL | 6% | — | — |
| Endothelial function | |||
| Reactive hyperemia (%)a | 61.5 (46.3, 83.3) | 59.2 (44.9, 82.2) | 66.9 (51.9, 85.6) |
| Flow‐mediated dilation (%)a | 4.0 (2.6, 5.5) | 3.9 (2.6, 5.4) | 4.2 (2.6, 5.6) |
ART indicates antiretroviral therapy; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NNRTI, non‐nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; VL, viral load.
a
Continuous variables were summarized as median (interquartile range).